ArticleOphthalmology science2026
Randomized Clinical Trial of Diffusion Optics Technology Spectacle Lenses in a Chinese Population (CATHAY): 12-Month Results.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate 12-month myopia control efficacy of diffusion optics technology (DOT) spectacle lenses in a Chinese population (CATHAY study). Design: Interim analysis of 6-month and 12-month data from a 24-month, randomized controlled clinical trial across 5 Chinese hospital sites, evaluating DOT spectacle lenses versus control standard single-vision (SV) spectacle lenses. Participants: One hundred ninety-five myopic children aged 6-13 years were enrolled across 5 sites in China. Participants were dispensed DOT lenses in a 2:1 ratio versus SV. Methods: Participants were randomized to DOT or SV spectacles. Axial length (AL) and cycloplegic spherical equivalent refraction (cSER) were measured at baseline, 6 months, and 12 months. Main Outcome Measures: Twelve-month changes in AL and cSER from baseline. Results: One hundred eighty-six children (DOT 128, SV 58) completed the 12-month visit (modified intent-to-treat cohort) with a mean age at prerandomization eligibility visit (baseline) of 9.6 ± 1.8 years. No severe adverse events were observed in either group. For DOT wearers, the mean observed change ± standard deviation in AL was 0.09 ± 0.22 (95% confidence interval [CI]: 0.05 to 0.13), and cSER change was -0.16 ± 0.51 D (95% CI: -0.25 to -0.07). For the SV group, mean observed change from baseline at 12 months for AL was 0.35 ± 0.19 mm (95% CI: 0.30-0.40), and cSER change was -0.64 ± 0.42 D (95% CI: -0.76 to -0.53). The least squares mean differences (±standard error) in AL elongation and cSER progression were significantly lower for DOT vs. SV at 12 months. The difference in AL change between DOT and SV was -0.26 ± 0.03 mm ( Conclusions: The 12-month interim results from this ongoing trial demonstrate the effectiveness of DOT spectacles for reducing myopic progression and axial elongation in Chinese children. A lens design based on the modulation of contrast on the retina works favorably for young Chinese children. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.